enGene, J&J deal

enGene partnered with Johnson & Johnson’s Janssen Biotech Inc. unit to develop enGene’s EG-12 to treat inflammatory bowel disease (IBD). enGene and Janssen will jointly develop EG-12 through clinical proof of mechanism in IBD patients, after which Janssen will have an option to receive exclusive, worldwide rights to develop EG-12 in all indications. Janssen also receives the right to explore the use of enGene’s non-viral vector gene delivery platform to deliver a payload against an additional undisclosed target. EG-12 delivers DNA carrying IL-10 to the gut. ...